Biontech investor Thomas Strüngmann talks about the success of the Mainz-based company, about the factors that contributed to it and how he sees the future of Germany as a pharmaceutical location.
He and his brother Andreas Strüngmann were not at all happy that this prize bears their name, says Thomas Strüngmann. The award is endowed with 100,000 euros and is intended to honor outstanding entrepreneurs who establish revolutionary technologies in the life sciences sector, according to the description. So basically people like the twins themselves, as will be made clear at the awards ceremony on Friday in Munich. The first prize winner is the Swiss company Haya Therapeutics. It develops drugs based on RNA, albeit a different class than the messenger RNA that Biontech uses for its vaccine. The twin brothers are involved in the Mainz-based company through their family holding company Athos – and it will stay that way.
